List view / Grid view
23 September 2016 | By BBI Solutions
BBI Solutions has launched Morffi™, a novel conjugate blocking technology that enhances signal intensity and improves the sensitivity of lateral flow immunoassays, at the Lateral Flow Test Development seminar in Seattle, USA, on the 20th September...
23 September 2016 | By CI Precision
Global consumer goods group RB (formerly known as Reckitt Benckiser) is implementing CI Precision’s MES solution (Ci-DMS) in the dispensing area at their manufacturing plant in Pakistan...
21 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Fewer serious adverse events were seen with semaglutide vs placebo; however, treatment discontinuation due to adverse events was more frequent...
21 September 2016 | By Coulter Partners
Global Life Sciences search specialist, Coulter Partners is pleased to announce a number of new appointments in the US and in London...
21 September 2016 | By Niamh Louise Marriott, Digital Content Producer
T-Guard has been shown to be well tolerated, with a manageable side effect profile and no severe infusion reactions in patients with acute GVHD...
20 September 2016 | By Niamh Louise Marriott, Digital Content Producer
She will succeed Andrew Witty as GSK CEO, when he retires on 31st March 2017. She will be the first female CEO of a major global pharmaceuticals company...
20 September 2016 | By WHEATON®
New line of purpose-built, ready-to-sterilize, uniquely barcoded vials will be introduced at the American Association of Clinical Chemistry Annual Meeting...
20 September 2016 | By Niamh Louise Marriott, Digital Content Producer
This study was the first in man Phase 1 clinical trial for an mGluR4 positive allosteric modulator. The randomised, double-blind, placebo controlled single and multiple ascending dose studies were designed to assess safety and tolerability of PXT002331 dosed orally...
20 September 2016 | By Edinburgh Instruments
Research in optical materials is rapidly moving towards stable, high-power laser sources emitting in the mid-infrared (mid-IR) region...
20 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Cachexia is a condition of involuntary weight loss, undernourishment and a number of negative side-effects that can be seen in patients with Chronic obstructive pulmonary disease (COPD), as well as in cancer and in several severe inflammatory diseases, such as AIDS, congestive heart failure, tuberculosis and rheumatoid arthritis...
20 September 2016 | By Niamh Louise Marriott, Digital Content Producer
In a notice from the FDA, the Prescription Drug User Fee Act date for its Priority Review of telotristat etiprate has been extended by three months...
20 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Obinutuzumab with bendamustine is used to treat follicular lymphoma in people who did not respond to, or whose condition has progressed after treatment...
20 September 2016 | By Niamh Louise Marriott, Digital Content Producer
CUVITRU is a treatment for patients with primary immunodeficiency (PI), a group of more than 300 genetic disorders in which part of the body's immune system is missing or functions improperly...
20 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Mino-Lok is being developed as an adjunctive therapy for the treatment of catheter-related or central line associated bloodstream infection (CRBSI/CLABSI)...
20 September 2016 | By Niamh Louise Marriott, Digital Content Producer
APX001 is a small molecule drug candidate that targets and inhibits the conserved fungal enzyme Gwt1, compromising fungal growth of major fungal pathogens...
